Oestrogen receptor gene (ESRI) amplification is frequent in endometrial carcinoma and its precursor lesions

Journal of Pathology

Volumn 216, Issue 2, 2008, Pages 151-157

  Lebeau, A ^a   Grob, T J ^a   Hoist, F ^a   Seyedi Fazlollahi, N ^a   Moch, H ^b   Terracciano, Luigi ^c   Turzynski, A ^d   Choschzick, M ^a   Sauter, G ^a   Simon, R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Consultant in Pathology ^*  (Germany)

Author keywords

Amplification; Endometrial carcinoma; ESR1; Oestrogen receptor; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN RECEPTOR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FREQUENCY ANALYSIS; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PRECANCEROUS CONDITIONS; SURVIVAL ANALYSIS;

EID: 53149151034     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2405     Document Type: Article

References (22)

1. Ferlav J. Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
2. Kitchener H. Management of endometrial cancer. Eur J Surg Oncol 2006;32:838-843.
3. Silverherg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Tumours of the Uterine Corpus: Epithelial Tumors and Related Lesions. Tavassoli FA, Devilee P (eds). IARC Press: Lyon. 2003; 221-249.
4. Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:364-367.
5. ACOG. Committee Opinion No. 336: tamoxifen and uterine cancer. Ohstet Gynecol 2006;107:1475-1478.
6. Hoist F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-660.
7. Wagner U, Bubendorf L, Gasser TC, Moch H, Gorog JP, Richter J, et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997;151:753-759.
8. Harvey JM, Clark GM, Osborne CK. Allied DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-hinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
9. Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995;59:347-351.
10. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-1470.
11. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 1993;50:281-286.
12. Carcangiu ML, Chambers JT, Voynick IM. Pino M, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part 1: Clinical and histologic correlations. Am J Clin Pathol 1990;94:247-254.
13. Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys 1989;17:21-27.
14. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecnl 1988;158:796-807.
15. Geisinger KR, Marshall RB, Kute TE, Homesley HD. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 1986;58:1506-1517.
16. Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang SB, et al. Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 2006;239:198-204.
17. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 2001;438:470-477.
18. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-2385.
19. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 1988;67:531-537.
20. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-2312.
21. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004;92:255-264.
22. Barlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A. Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 1997;20:372-376.